About 1.3 million humans in the United States are affected each year by Cachexia, which is a weakness and wasting away of the body due to severe illnesses such as cancer, multiple sclerosis, Parkinson’s disease, HIV/AIDS and other progressive diseases. Cachexia is secondary to an underlying disease such as cancer or AIDS and is a positive risk factor for death. It is often seen at the end-stage of cancer. Cancer induced cachexia is responsible for about 20% of all cancer deaths. It physically weakens patients to the extent that response to standard treatments is poor.
Use of Cannabinoids
Delta-9-tetrahydrocannabinol (THC), a constituent of cannabis, has been used as an anti-emetic drug in cancer patients receiving chemotherapy. THC has also shown stimulation of appetite and increase of body weight in HIV-positive and cancer patients. (Gorter, 1999).
IGC has applied for a U.S patent based on a novel therapy using cannabinoids and other drugs to treat Cachexia. Our filing provides methods and compositions for treating cachexia and eating disorders in humans and veterinary animals.